Drug profile · INN
ranolazine
RANEXA (PREVIOUSLY LATIXA)
ranolazine (RANEXA (PREVIOUSLY LATIXA)) is a sodium channel protein type iv alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — ranolazine
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 0
- Programs
- 20
- Data quality
- 0.89
Quick answer
ranolazine (RANEXA (PREVIOUSLY LATIXA)) is a sodium channel protein type iv alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel protein type IV alpha subunit blocker
Primary target: Sodium channel protein type 4 subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ranolazine?
ranolazine (RANEXA (PREVIOUSLY LATIXA)) is a sodium channel protein type iv alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ranolazine?
RANEXA (PREVIOUSLY LATIXA) is a marketed brand name for ranolazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranolazine?
ranolazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.